This document summarizes the primary findings of that meeting and describes some of the major impediments that currently limit widespread and consistent access to optimally formulated, qualityassured treatment. These challenges are examined across both government-run health services and private health providers - sectors that pose significantly different challenges and will require di!erent solutions. Ensuring that all patients receive adequate treatment will require addressing the challenges in both sectors. The document also looks at some of the critical gaps in current knowledge and areas of concern that may need further research.
Finally, the document discusses the important roles that key actors, including national TB programs, regulatory agencies, international donors, manufacturers and others, can play in strengthening medicine management. It highlights a number of key recommended actions that can be taken to address impediments to TB care.